124 related articles for article (PubMed ID: 14724570)
1. Wild-type p53 gene transfer is not detrimental to normal cells in vivo: implications for tumor gene therapy.
Bossi G; Mazzaro G; Porrello A; Crescenzi M; Soddu S; Sacchi A
Oncogene; 2004 Jan; 23(2):418-25. PubMed ID: 14724570
[TBL] [Abstract][Full Text] [Related]
2. Expression of exogenous wt-p53 does not affect normal hematopoiesis: implications for bone marrow purging.
Scardigli R; Bossi G; Blandino G; Crescenzi M; Soddu S; Sacchi A
Gene Ther; 1997 Dec; 4(12):1371-8. PubMed ID: 9472561
[TBL] [Abstract][Full Text] [Related]
3. Development of a murine orthotopic model of leukemia: evaluation of TP53 gene therapy efficacy.
Bossi G; Scardigli R; Musiani P; Martinelli R; Gentileschi MP; Soddu S; Sacchi A
Cancer Gene Ther; 2000 Jan; 7(1):135-43. PubMed ID: 10678366
[TBL] [Abstract][Full Text] [Related]
4. Friend leukemia virus infection enhances DNA damage-induced apoptosis of hematopoietic cells, causing lethal anemia in C3H hosts.
Kitagawa M; Yamaguchi S; Hasegawa M; Tanaka K; Sado T; Hirokawa K; Aizawa S
J Virol; 2002 Aug; 76(15):7790-8. PubMed ID: 12097591
[TBL] [Abstract][Full Text] [Related]
5. Exogenous wt-p53 protein is active in transformed cells but not in their non-transformed counterparts: implications for cancer gene therapy without tumor targeting.
D'Orazi G; Marchetti A; Crescenzi M; Coen S; Sacchi A; Soddu S
J Gene Med; 2000; 2(1):11-21. PubMed ID: 10765501
[TBL] [Abstract][Full Text] [Related]
6. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
7. The C terminus of p53 regulates gene expression by multiple mechanisms in a target- and tissue-specific manner in vivo.
Hamard PJ; Barthelery N; Hogstad B; Mungamuri SK; Tonnessen CA; Carvajal LA; Senturk E; Gillespie V; Aaronson SA; Merad M; Manfredi JJ
Genes Dev; 2013 Sep; 27(17):1868-85. PubMed ID: 24013501
[TBL] [Abstract][Full Text] [Related]
8. Myeloproliferative disease and myelodysplastic syndrome induced by transplantation of bone marrow cells expressing mutant p53.
Shounan Y; MacKenzie K; Dolnikov A; Miller M; Symonds G
Leukemia; 1997 Oct; 11(10):1641-9. PubMed ID: 9324283
[TBL] [Abstract][Full Text] [Related]
9. Retrovirus vector containing wild type p53 gene and its effect on human glioma cells.
Hlavatý J; Tyukosova S; Bies J; Hlubinova K; Altaner C
Neoplasma; 2000; 47(4):204-11. PubMed ID: 11043823
[TBL] [Abstract][Full Text] [Related]
10. Activation of endogenous p53 by combined p19Arf gene transfer and nutlin-3 drug treatment modalities in the murine cell lines B16 and C6.
Merkel CA; da Silva Soares RB; de Carvalho AC; Zanatta DB; Bajgelman MC; Fratini P; Costanzi-Strauss E; Strauss BE
BMC Cancer; 2010 Jun; 10():316. PubMed ID: 20569441
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of nonthreshold leukemogenic response to methyl nitrosourea in p53-deficient C3H/He mice.
Hirabayashi Y; Yoshida K; Aizawa S; Kodama Y; Kanno J; Kurokawa Y; Yoshimura I; Inoue T
Toxicol Appl Pharmacol; 2003 Aug; 190(3):251-61. PubMed ID: 12902196
[TBL] [Abstract][Full Text] [Related]
12. Stem-cell leukemia: p53 deficiency mediated suppression of leukemic differentiation in C3H/He myeloid leukemia.
Yoshida K; Aizawa S; Watanabe K; Hirabayashi Y; Inoue T
Leuk Res; 2002 Dec; 26(12):1085-92. PubMed ID: 12443880
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo purging by adenoviral p53 gene therapy does not affect NOD-SCID repopulating activity of human CD34+ cells.
Hirai M; LaFace D; Robinson S; Kelsey L; Johnson R; Wen SF; Warkentin P; Mills K; Vaillancourt M; Chavez J; Leutzinger C; Sumegi J; Neugebauer S; Lehman J; Talmadge C; Maneval D; Talmadge J
Cancer Gene Ther; 2001 Dec; 8(12):936-47. PubMed ID: 11781656
[TBL] [Abstract][Full Text] [Related]
14. Wild-type p53 induces diverse effects in 32D cells expressing different oncogenes.
Soddu S; Blandino G; Scardigli R; Martinelli R; Rizzo MG; Crescenzi M; Sacchi A
Mol Cell Biol; 1996 Feb; 16(2):487-95. PubMed ID: 8552075
[TBL] [Abstract][Full Text] [Related]
15. p53 trans-dominantly suppresses tumor formation of human breast cancer cells mediated by retroviral bulk infection without marker gene selection: an expeditious in vitro protocol with implications towards gene therapy.
Runnebaum IB; Kreienberg R
Hybridoma; 1995 Apr; 14(2):153-7. PubMed ID: 7590773
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia.
Folkerts H; Hilgendorf S; Wierenga ATJ; Jaques J; Mulder AB; Coffer PJ; Schuringa JJ; Vellenga E
Cell Death Dis; 2017 Jul; 8(7):e2927. PubMed ID: 28703806
[TBL] [Abstract][Full Text] [Related]
17. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect.
Nishizaki M; Fujiwara T; Tanida T; Hizuta A; Nishimori H; Tokino T; Nakamura Y; Bouvet M; Roth JA; Tanaka N
Clin Cancer Res; 1999 May; 5(5):1015-23. PubMed ID: 10353734
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect of intratumoral administration of bone marrow-derived dendritic cells transduced with wild-type p53 gene.
Murakami T; Tokunaga N; Waku T; Gomi S; Kagawa S; Tanaka N; Fujiwara T
Clin Cancer Res; 2004 Jun; 10(11):3871-80. PubMed ID: 15173096
[TBL] [Abstract][Full Text] [Related]
19. Levels of p53 protein increase with maturation in human hematopoietic cells.
Kastan MB; Radin AI; Kuerbitz SJ; Onyekwere O; Wolkow CA; Civin CI; Stone KD; Woo T; Ravindranath Y; Craig RW
Cancer Res; 1991 Aug; 51(16):4279-86. PubMed ID: 1868448
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous genetic chemoprotection of normal marrow cells and genetic chemosensitization of breast cancer cells in a mouse cancer gene therapy model.
Hanania EG; Deisseroth AB
Clin Cancer Res; 1997 Feb; 3(2):281-6. PubMed ID: 9815684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
